Correction: First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. BMJ Publishing Group.
Chicago Style (17th ed.) CitationCorrection: First Use of Cenerimod, a Selective S1P1 Receptor Modulator, for the Treatment of SLE: A Double-blind, Randomised, Placebo-controlled, Proof-of-concept Study. BMJ Publishing Group.
MLA (9th ed.) CitationCorrection: First Use of Cenerimod, a Selective S1P1 Receptor Modulator, for the Treatment of SLE: A Double-blind, Randomised, Placebo-controlled, Proof-of-concept Study. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.